Boehringer Ingelheim International Gmbh

Edgar Falkner

Ingrid Maurer-Fogy

Gerhard Bodo

Rudolf Hauptmann

Peter Swetly

Gunther R Adolf

Christian Stratowa

Christiaan Maria Reutelingsperger

Peter Meindl

Tilman Voss

Silvia J Lindner

This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.

Vascular anticoagulant proteins DNA which codes them, processer for

Methods and vectors for expressing interferon-alpha (IFN-.alpha.) proteins in E. coli are provided. Use of a vector comprising an IFN-.alpha. sequence fused to an E. coli heat-stable enterotoxin signal sequence (STII) under the control of the E. coli phosphatase (phoA) promoter affords high levels of correctly-folded and -processed, biologically active IFN-.alpha. polypeptides.

Process and vector for expressing alpha-interferon in E. coli

A process for the preparation and purification of recombinant Interferon-.alpha. is disclosed. The invention is directed to a process comprising the following steps: cultivating E. coli containing the interferon gene for a growth period during which not more than 5% methionine-interferon is formed; extracting and concentrating the expressed interferon; subjecting the preliminarily purified material to Tandem Chromatography, wherein the Tandem Chromatography comprises separation on a cellulose column followed by an anti-alpha-interferon monoclonal antibody affinity column; subjecting the thus purified material to isoelectric precipitation of impurities at about pH 4.0 to about pH 4.8; and purifying the interferon by chromatography on a high performance cation exchange column using a volatile buffer, wherein the purified interferon is non-immunogenic when administered parenterally to a human.

Process for preparing and purifying alpha-interferon

This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,

Hybrid interferons, their use as pharmaceutical compositions and as

Growing community of inventors

Vienna, Austria

Edgar Falkner